AI Portfolio Summary
In 2025 Q4, BVF INC/IL maintained a portfolio of 48 distinct positions. The most significant new addition to the portfolio was DISC MEDICINE INC, which now represents 1.74% of the total fund value. They heavily accumulated shares in STRUCTURE THERAPEUTI, increasing their position by 8.6%. Conversely, BVF INC/IL completely exited their position in NLS PHARMACEUTICS LT.
Total Positions
48
Quarter
2025 Q4
Top Holding
KYMR (14.4%)
Top 10 Concentration
62.8%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-48 of 48
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
KYMR
KYMERA THERAPEU...
|
Healthcare | 14.41% | 12.63% |
#1
Prev: #1
|
7.0 | no change | no change |
P
S
|
5,502,710 | $428,165,865 | 2020 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RVMD
REVOLUTION MEDI...
|
Healthcare | 9.00% | 7.52% |
#2
Prev: #2
|
5.6 | -618,131 | -15.6% |
P
S
|
3,356,782 | $267,367,686 | 2020 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MLTX
MOONLAKE IMMUNO...
|
Healthcare | 8.76% | 5.74% |
#3
1
Prev: #4
|
5.5 | no change | no change |
P
S
|
19,751,284 | $260,321,923 | 2022 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GPCR
STRUCTURE THERA...
|
Healthcare | 8.15% | 3.64% |
#4
5
Prev: #9
|
5.8 | 275,105 | 8.6% |
P
S
|
3,479,022 | $241,965,980 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OLMA
OLEMA PHARMACEU...
|
Healthcare | 4.46% | 2.10% |
#5
13
Prev: #18
|
3.3 | no change | no change |
P
S
|
5,295,893 | $132,397,325 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MIRM
MIRUM PHARMACEU...
|
Healthcare | 3.98% | 4.44% |
#6
1
Prev: #7
|
2.6 | no change | no change |
P
S
|
1,495,290 | $118,112,957 | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GHRS
GH RESEARCH PLC
|
Healthcare | 3.77% | 5.12% |
#7
1
Prev: #6
|
2.5 | no change | no change |
P
S
|
8,827,712 | $112,111,942 | 2021 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XNCR
XENCOR INC
|
Healthcare | 3.68% | 1.30% |
#8
18
Prev: #26
|
4.5 | 4,393,579 | 160.3% |
P
S
|
7,133,720 | $109,217,253 | 2013 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ZYME
ZYMEWORKS INC
|
Healthcare | 3.49% | 2.73% |
#9
5
Prev: #14
|
2.4 | no change | no change |
P
S
|
3,938,641 | $103,704,418 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PVLA
PALVELLA THERAP...
|
Healthcare | 3.10% | 2.95% |
#10
2
Prev: #12
|
1.2 | -282,240 | -24.3% |
P
S
|
879,009 | $92,005,872 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KURA
KURA ONCOLOGY I...
|
Healthcare | 3.01% | 3.09% |
#11
1
Prev: #10
|
2.2 | no change | no change |
P
S
|
8,617,162 | $89,532,313 | 2017 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
STOK
STOKE THERAPEUT...
|
Healthcare | 2.42% | 1.58% |
#12
11
Prev: #23
|
3.5 | 608,578 | 36.7% |
P
S
|
2,265,674 | $71,912,493 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XOMA
XOMA ROYALTY CO...
|
Healthcare | 2.32% | 4.05% |
#13
5
Prev: #8
|
1.9 | no change | no change |
P
S
|
2,590,303 | $68,876,157 | 2016 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABVX
ABIVAX SA
|
Healthcare | 2.31% | 1.92% |
#14
6
Prev: #20
|
1.4 | -50,000 | -9.0% |
P
S
|
508,031 | $68,510,521 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NKTR
NEKTAR THERAPEU...
|
Healthcare | 2.22% | 2.94% |
#15
2
Prev: #13
|
3.4 | 283,000 | 22.2% |
P
S
|
1,559,595 | $65,939,677 | 2007 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ACIU
AC IMMUNE SA
|
Healthcare | 2.10% | 2.32% |
#16
Prev: #16
|
1.8 | no change | no change |
P
S
|
19,822,436 | $62,242,449 | 2018 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GLUE
MONTE ROSA THER...
|
Healthcare | 2.02% | 1.70% |
#17
4
Prev: #21
|
0.8 | -1,824,246 | -32.2% |
P
S
|
3,835,886 | $60,146,692 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CGEM
CULLINAN THERAP...
|
Healthcare | 2.00% | 1.38% |
#18
6
Prev: #24
|
1.8 | no change | no change |
P
S
|
5,750,683 | $59,519,569 | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TYRA
TYRA BIOSCIENCE...
|
Healthcare | 1.88% | 2.07% |
#19
Prev: #19
|
0.8 | -1,522,129 | -41.7% |
P
S
|
2,127,665 | $55,936,313 | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IRON
DISC MEDICINE I...
|
Healthcare | 1.74% | — |
#20
Prev: #—
|
4.2 | 650,000 | no change |
NEW
|
650,000 | $51,616,500 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IMCR
IMMUNOCORE HLDG...
|
Healthcare | 1.69% | 2.32% |
#21
4
Prev: #17
|
1.2 | -85,313 | -5.4% |
P
S
|
1,488,975 | $50,293,922 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IVVD
INVIVYD INC
|
Healthcare | 1.62% | — |
#22
Prev: #—
|
4.1 | 19,525,000 | no change |
NEW
|
19,525,000 | $48,226,750 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SEPN
SEPTERNA INC
|
Healthcare | 1.61% | 3.06% |
#23
12
Prev: #11
|
0.6 | -2,295,008 | -57.1% |
P
S
|
1,720,782 | $47,975,402 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ANNX
ANNEXON INC
|
Healthcare | 1.54% | 0.87% |
#24
4
Prev: #28
|
3.1 | 2,128,080 | 30.4% |
P
S
|
9,128,080 | $45,822,962 | 2022 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CMPX
COMPASS THERAPE...
|
Healthcare | 1.40% | 0.67% |
#25
6
Prev: #31
|
3.6 | 3,014,842 | 63.5% |
P
S
|
7,764,842 | $41,697,202 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
FDMT
4D MOLECULAR TH...
|
Healthcare | 1.17% | 1.63% |
#26
4
Prev: #22
|
1.5 | no change | no change |
P
S
|
4,629,289 | $34,719,668 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
CRESCENT BIOPHA...
|
—
|
Unknown | 1.10% | 0.67% |
#27
5
Prev: #32
|
3.4 | 1,360,900 | 98.1% |
P
S
|
2,748,763 | $32,600,329 | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
FHTX
FOGHORN THERAPE...
|
Healthcare | 0.96% | 1.05% |
#28
1
Prev: #27
|
1.4 | no change | no change |
P
S
|
5,302,000 | $28,630,800 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RPTX
REPARE THERAPEU...
|
Healthcare | 0.90% | 0.74% |
#29
Prev: #29
|
1.4 | no change | no change |
P
S
|
10,333,600 | $26,867,360 | 2020 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AVTX
AVALO THERAPEUT...
|
Healthcare | 0.83% | 0.70% |
#30
Prev: #30
|
0.8 | 1 | 0.0% |
P
S
|
1,355,257 | $24,611,467 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PEPG
PEPGEN INC
|
Healthcare | 0.42% | 0.36% |
#31
4
Prev: #35
|
1.2 | no change | no change |
P
S
|
1,915,000 | $12,466,650 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ELDN
ELEDON PHARMACE...
|
Healthcare | 0.32% | 0.66% |
#32
1
Prev: #33
|
1.1 | no change | no change |
P
S
|
6,293,282 | $9,502,856 | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XFOR
X4 PHARMACEUTIC...
|
Healthcare | 0.30% | 0.31% |
#33
3
Prev: #36
|
1.1 | no change | no change |
P
S
|
2,233,742 | $8,934,968 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AXSM
AXSOME THERAPEU...
|
Healthcare | 0.28% | 2.40% |
#34
19
Prev: #15
|
0.1 | -441,000 | -90.6% |
P
S
|
45,757 | $8,357,058 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MOLN
MOLECULAR PARTN...
|
Healthcare | 0.20% | 0.20% |
#35
4
Prev: #39
|
1.1 | no change | no change |
P
S
|
1,353,968 | $5,822,062 | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IMA
IMAGENEBIO INC
|
Healthcare | 0.19% | 0.26% |
#36
2
Prev: #38
|
1.1 | no change | no change |
P
S
|
802,102 | $5,534,504 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TCRX
TSCAN THERAPEUT...
|
Healthcare | 0.18% | 0.39% |
#37
3
Prev: #34
|
1.1 | no change | no change |
P
S
|
5,226,074 | $5,226,074 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TENX
TENAX THERAPEUT...
|
Healthcare | 0.14% | 0.10% |
#38
3
Prev: #41
|
1.1 | no change | no change |
P
S
|
339,549 | $4,139,102 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IMUX
IMMUNIC INC
|
Healthcare | 0.14% | 0.27% |
#39
2
Prev: #37
|
1.1 | no change | no change |
P
S
|
7,652,972 | $4,084,391 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IVA
INVENTIVA SA
|
Healthcare | 0.11% | 0.16% |
#40
Prev: #40
|
1.0 | no change | no change |
P
S
|
686,040 | $3,190,086 | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ENGNW
ENGENE HOLDINGS...
|
Unknown | 0.08% | 0.03% |
#41
4
Prev: #45
|
1.0 | no change | no change |
P
S
|
945,402 | $2,401,321 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NLSP
NLS PHARMACEUTI...
|
Unknown | 0.00% | 0.01% |
Sold All 😨
(Was: #46) |
0.0 | -143,676 | -100.0% |
CLOSED
|
— | $— | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
FBRX
FORTE BIOSCIENC...
|
Healthcare | 0.00% | 0.04% |
Sold All 😨
(Was: #44) |
0.0 | -65,350 | -100.0% |
CLOSED
|
— | $— | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SABS
SAB BIOTHERAPEU...
|
Healthcare | 0.00% | 0.08% |
Sold All 😨
(Was: #43) |
0.0 | -932,697 | -100.0% |
CLOSED
|
— | $— | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EPIX
ESSA PHARMA INC
|
Unknown | 0.00% | 0.09% |
Sold All 😨
(Was: #42) |
0.0 | -11,668,473 | -100.0% |
CLOSED
|
— | $— | 2018 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CELC
CELCUITY INC
|
Healthcare | 0.00% | 1.32% |
Sold All 😨
(Was: #25) |
0.0 | -658,421 | -100.0% |
CLOSED
|
— | $— | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CDTX
CIDARA THERAPEU...
|
Healthcare | 0.00% | 5.49% |
Sold All 😨
(Was: #5) |
0.0 | -1,414,165 | -100.0% |
CLOSED
|
— | $— | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PTGX
PROTAGONIST THE...
|
Healthcare | 0.00% | 6.90% |
Sold All 😨
(Was: #3) |
0.0 | -2,560,916 | -100.0% |
CLOSED
|
— | $— | 2016 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-48 of 48 holdings